At least a dozen portable cholesteroltesting instruments have been designed for use in community and office settings. These instruments have made mass screenings for this risk factor feasible and thus are now in widespread use for this purpose.
Intodwtion Results
At least a dozen portable cholesteroltesting instruments have been designed for use in community and office settings. These instruments have made mass screenings for this risk factor feasible and thus are now in widespread use for this purpose.
To address questions concerning the reliability of this technology, the National Heart, Lung, and Blood Institute supported three projects entitled the Model Systems for Blood Cholesterol Screening Program (MSBCSP).' A primary MSBCSP objective was to test the accuracy, precision, and durability of portable analyzers under the usual operating conditions associated with screenings. This article reports findings from Massachusetts' MSBCSP concerning the Reflotron, the lengthiest field evaluation thus far reported. For Reflotrons 1, 3, and 4, the weighted average of all values met the current precision goal set by the National Cholesterol Education Program's Laboratory Standardization Panel (LSP) for all three QC levels, but it fell short ofthe 1992 LSP standards for all levels.3 For Reflotron 2, the weighted average of the values met the current LSP standards for all QC levels, but the 1992 standards were attained for only two levels (see Table 1 ).
Metods
The bias of the four instruments varied from -3.3% to +3.2%. The differences among the Reflotrons were statistically significant (ANOVA F = 25.4, P < .0001). All four analyzers met the current LSP standards; only two met the 1992 standards.
As demonstrated in Figure 1 , monthly bias on the Reflotron fluctuated considerably. For example, the bias ranged from -6.0% to +2.9% on Reflotron 1. Similar variations were seen on the other Reflotrons. Figure 2 
Diussion
The Reflotron has been marketed aggressively for use in community screening programs. The marketing has focused heavily on the instrument's relatively low cost, ease of operation, and accuracy. This strategy has resulted in the widespread use ofthis instrument in blood cholesterol screenings.
As shown in Table 2 , the Reflotron has been studied previously using various settings, sample sizes, and methodologies.4-21 When placed in the context of these other studies, our results lead to concerns about the widespread usage of the Reflotron. The first concern is that the instrument is not sufficiently precise. Although it does meet current standards, it clearly will not be able to meet the 1992 standards without substantial modifications. Our second concern is that the Reflotron does not 
